Literature DB >> 12394179

Hemoglobin-based oxygen carriers.

Christopher P Stowell1.   

Abstract

Three types of materials have been studied as candidate blood substitutes: the perfluorocarbons, modified hemoglobins, and liposome-encapsulated hemoglobin. Progress has been greatest with the hemoglobin-based oxygen carriers. Hemoglobin is a highly active molecule; hence, modification has been required to avoid potential deleterious effects. Although there has been considerable progress toward bringing such a product to the clinic, its development has challenged understanding of oxygen delivery and use. The study of these molecules has provided new insights into basic physiologic processes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12394179     DOI: 10.1097/00062752-200211000-00013

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  5 in total

1.  Modulation of oxidative stability of haemoglobin inside liposome-encapsulated haemoglobin.

Authors:  Vibhudutta Awasthi; Vivek R Yadav; Beth Goins; William T Phillips
Journal:  J Microencapsul       Date:  2012-12-11       Impact factor: 3.142

2.  Magnetic resonance spectroscopy for evaluation of liposome-encapsulated hemoglobin as a resuscitation fluid.

Authors:  Vibhudutta Awasthi; H Agashe; S Doblas; R Towner
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  2010-04

3.  Functional characterization of the purified holo form of hemoglobin I from Lucina pectinata overexpressed in Escherichia coli.

Authors:  Evys Collazo; Ruth Pietri; Walleska De Jesús; Cacimar Ramos; Ana Del Toro; Ruth Gretchen León; Carmen L Cadilla; Juan López-Garriga
Journal:  Protein J       Date:  2004-05       Impact factor: 2.371

Review 4.  Doping with artificial oxygen carriers: an update.

Authors:  Yorck Olaf Schumacher; Michael Ashenden
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

Review 5.  What happened to blood substitutes?

Authors:  C P Stowell
Journal:  Transfus Clin Biol       Date:  2005-12-01       Impact factor: 1.406

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.